CytoDyn (CYDY) FCF Margin (2021 - 2022)

CytoDyn (CYDY) posted FCF Margin of 17776.47% for Q2 2022, down 38.42% on a QoQ basis from 12842.67% in Q4 2021.

CytoDyn (CYDY) FCF Margin (2021 - 2022) Analysis & Trends

CytoDyn's FCF Margin history runs 2 years deep, the most recent figure standing at 17776.47% for Q2 2022.

Quarterly FCF Margin changed N/A year-over-year to 17776.47% in Q2 2022, while the trailing twelve-month figure through May 2022 was 25917.67% (changed N/A YoY) and the FY2022 annual result came in at 25907.67%, changed N/A from the prior year.
FCF Margin was 17776.47% for Q2 2022 at CytoDyn, down from 12842.67% in the prior quarter.
Across five years, FCF Margin topped out at 12842.67% in Q4 2021 and bottomed at 77436.59% in Q3 2021.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	10.45%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	43.35%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.53%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	CytoDyn	267.79 Mn	267.79 Mn	-	-

Historic Data

Download Data

Date	Value
May 31, 2022	-17,776.47%
Nov 30, 2021	-12,842.67%
Aug 31, 2021	-77,436.59%